Xenograft and genetically engineered mouse model systems of osteosarcoma and Ewing's sarcoma: Tumor models for cancer drug discovery

Expert Opinion on Drug Discovery

Volumn 8, Issue 10, 2013, Pages 1181-1189

  Sampson, Valerie B ^a   Kamara, Davida F ^a   Kolb, E Anders ^a  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

Bone sarcoma; Ewing's sarcoma; Genetically engineered mouse; Osteosarcoma; Soft tissue sarcoma; Xenograft

Indexed keywords

BIOLOGICAL MARKER; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DASATINIB; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; IFOSFAMIDE; METHOTREXATE; MITOMYCIN; NEW DRUG; RAPAMYCIN; RIDAFOROLIMUS; ROBATUMUMAB; SORAFENIB; TEMSIROLIMUS; VINBLASTINE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER GROWTH; CANCER MODEL; CANCER SURVIVAL; CYTOGENETICS; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; DRUG TOLERABILITY; EWING SARCOMA; FUSION GENE; GENE EXPRESSION; GENETICALLY ENGINEERED MOUSE STRAIN; HUMAN; IMMUNE SYSTEM; IN VIVO STUDY; KARYOTYPE; METASTASIS; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; DRUG DISCOVERY; MICE; MICE, TRANSGENIC; OSTEOSARCOMA; SARCOMA, EWING; SARCOMA, EXPERIMENTAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884643275     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2013.817988     Document Type: Review

References (74)

1. Ordonez JL, Osuna D, Garcia-Dominguez DJ, et al. The clinical relevance of molecular genetics in soft tissue sarcomas. Adv Anat Pathol 2010;17(3):162-81
2. Bennicelli JL, Barr FG. Chromosomal translocations and sarcomas. Curr Opin Oncol 2002;14(4):412-19
3. Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol 2000;13(10):1134-42
4. Osuna D, de Alava E. Molecular pathology of sarcomas. Rev Recent Clin Trials 2009;4(1):12-26
5. Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003;39(14):2006-11
6. Talmadge JE, Singh RK, Fidler IJ, Raz A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 2007;170(3):793-804
7. Dodd RD, Mito JK, Kirsch DG. Animal models of soft-tissue sarcoma. Dis Model Mech 2010;3(9-10):557-66
8. Rankin KS, Starkey M, Lunec J, et al. Of dogs and men: comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma. Pediatr Blood Cancer 2012;58(3):327-33
9. Holt PD. Consideration of tissue response in the application of the two-mutation model to radiation carcinogenesis. Int J Radiat Biol 1997;71(2):203-13
10. Rygaard J, Povlsen CO. Heterotransplantation of a human malignant tumour to Nude mice. Acta Pathol Microbiol Scand 1969;77(4):758-60 .. A landmark study for the development of tumors in immunocompromised mice.
11. Budach V, Stuschke M, Budach W, et al. Radioresponsiveness of a human soft tissue sarcoma xenograft to different single and fractionated regimens. Strahlenther Onkol 1989;165(7):513-14
12. Ng AJ, Mutsaers AJ, Baker EK, Walkley CR. Genetically engineered mouse models and human osteosarcoma. Clin Sarcoma Res 2012;2(1):19 . Comprehensive review of genetically engineered mouse models of human osteosarcoma.
13. Hansen MF. Genetic and molecular aspects of osteosarcoma. J Musculoskelet Neuronal Interact 2002;2(6):554-60
14. Tang N, Song WX, Luo J, et al. Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res 2008;466(9):2114-30
15. Gisselsson D, Palsson E, Hoglund M, et al. Differentially amplified chromosome 12 sequences in low-and high-grade osteosarcoma. Genes Chromosomes Cancer 2002;33(2):133-40
16. Qiu J, Zhu Q, Wang L, et al. Molecular cytogenetics of bone tumors. Zhonghua Wai Ke Za Zhi 2000;38(5):340-3
17. Fuchs B, Pritchard DJ. Etiology of osteosarcoma. Clin Orthop Relat Res 2002;397):40-52
18. El-Rifai W, Harper JC, Cummings OW, et al. Consistent genetic alterations in xenografts of proximal stomach and gastro-esophageal junction adenocarcinomas. Cancer Res 1998;58(1):34-7
19. Mayordomo E, Machado I, Giner F, et al. A tissue microarray study of osteosarcoma: histopathologic and immunohistochemical validation of xenotransplanted tumors as preclinical models. Appl Immunohistochem Mol Morphol 2010;18(5):453-61
20. Kuijjer ML, Namlos HM, Hauben EI, et al. mRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts. BMC Med Genomics 2011;4:66
21. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 2007;49(7):928-40 .. Description of a preclinical testing program of well-characterized models of childhood cancers using panels of xenograft tumors and cell lines.
22. Bruheim S, Bruland OS, Breistol K, et al. Human osteosarcoma xenografts and their sensitivity to chemotherapy. Pathol Oncol Res 2004;10(3):133-41
23. Takeshita H, Gebhardt MC, Springfield DS, et al. Experimental models for the study of drug resistance in osteosarcoma: P-glycoprotein-positive, murine osteosarcoma cell lines. J Bone Joint Surg Am 1996;78(3):366-75
24. Takeshita H, Kusuzaki K, Murata H, et al. Osteoblastic differentiation and P-glycoprotein multidrug resistance in a murine osteosarcoma model. Br J Cancer 2000;82(7):1327-31
25. Wu Z, Min L, Chen D, et al. Overexpression of BMI-1 promotes cell growth and resistance to cisplatin treatment in osteosarcoma. PLoS One 2011;6(2):e14648
26. Hingorani P, Zhang W, Gorlick R, Kolb EA. Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo. Clin Cancer Res 2009;15(10):3416-22
27. Yuan J, Ossendorf C, Szatkowski JP, et al. Osteoblastic and osteolytic human osteosarcomas can be studied with a new xenograft mouse model producing spontaneous metastases. Cancer Invest 2009;27(4):435-42
28. Sottnik JL, Duval DL, Ehrhart EJ, Thamm DH. An orthotopic, postsurgical model of luciferase transfected murine osteosarcoma with spontaneous metastasis. Clin Exp Metastasis 2010;27(3):151-60
29. Khanna C, Prehn J, Yeung C, et al. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin Exp Metastasis 2000;18(3):261-71
30. Zou CY, Wang J, Shen JN, et al. Establishment and characteristics of two syngeneic human osteosarcoma cell lines from primary tumor and skip metastases. Acta Pharmacol Sin 2008;29(3):325-32
31. Huang G, Yu L, Cooper LJ, et al. Genetically modified T cells targeting interleukin-11 receptor alpha-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Res 2012;72(1):271-81
32. Rainusso N, Brawley VS, Ghazi A, et al. Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma. Cancer Gene Ther 2012;19(3):212-17
33. Frese KK, Tuveson DA. Maximizing mouse cancer models. Nat Rev Cancer 2007;7(9):645-58
34. Sharpless NE, Depinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006;5(9):741-54
35. Stemmer-Rachamimov AO, Nielsen GP, Rosenberg AE, et al. The NF2 gene and merlin protein in human osteosarcomas. Neurogenetics 1998;2(1):73-4
36. Gokgoz N, Wunder JS, Mousses S, et al. Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma. Cancer 2001;92(8):2181-9
37. Walkley CR, Qudsi R, Sankaran VG, et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev 2008;22(12):1662-76
38. Berman SD, Calo E, Landman AS, et al. Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc Natl Acad Sci USA 2008;105(33):11851-6
39. Kawahara M, Takahashi Y, Takazawa K, et al. Caffeine dose-dependently potentiates the antitumor effect of cisplatin on osteosarcomas. Anticancer Res 2008;28(3A):1681-5
40. Jones KB. Osteosarcomagenesis: modeling cancer initiation in the mouse. Sarcoma 2011;2011:694136
41. Ludwig JA. Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future. Curr Opin Oncol 2008;20(4):412-18
42. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348(8):694-701
43. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992;359(6391):162-5
44. Kovar H, Zoubek A, Pfleiderer C, et al. The EWS gene rearrangement in Ewing tumors: key to the disease. Klin Padiatr 1994;206(4):196-200
45. Sorensen PH, Lessnick SL, Lopez-Terrada D, et al. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 1994;6(2):146-51
46. Balamuth NJ, Womer RB. Ewing's sarcoma. Lancet Oncol 2010;11(2):184-92
47. Lin PP, Wang Y, Lozano G. Mesenchymal Stem Cells and the Origin of Ewing's Sarcoma. Sarcoma 2011
48. Ross KA, Smyth NA, Murawski CD, Kennedy JG. The biology of ewing sarcoma. ISRN Oncol 2013;2013:759725
49. Riggi N, Cironi L, Provero P, et al. Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res 2005;65(24):11459-68
50. Tanaka K, Iwakuma T, Harimaya K, Sato H. Iwamoto Y. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J Clin Invest 1997;99(2):239-47
51. Toub N, Bertrand JR, Tamaddon A, et al. Efficacy of siRNA nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma. Pharm Res 2006;23(5):892-900
52. Barber-Rotenberg JS, Selvanathan SP, Kong Y, et al. Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1. Oncotarget 2012;3(2):172-82 . The first EWS-FLI1 targeted therapy with the potential for advancement for clinical studies.
53. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50(6):1190-7
54. Kurmasheva RT, Dudkin L, Billups C, et al. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 2009;69(19):7662-71
55. Houghton PJ, Morton CL, Gorlick R, et al. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2010;54(7):921-6
56. Kolb EA, Gorlick R, Maris JM, et al. Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 2012;58(5):729-35
57. Smith MA, Morton CL, Phelps DA, et al. Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;51(1):34-41
58. Lock RB, Carol H, Maris JM, et al. Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer 2013;60(7):E42-5
59. Kang MH, Reynolds CP, Houghton PJ, et al. Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer 2012;59(1):185-8
60. Lin PP, Pandey MK, Jin F, et al. EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model. Cancer Res 2008;68(21):8968-75
61. Torchia EC, Boyd K, Rehg JE, et al. EWS/FLI-1 induces rapid onset of myeloid/erythroid leukemia in mice. Mol Cell Biol 2007;27(22):7918-34
62. Ordonez JL, Osuna D, Herrero D, et al. Advances in Ewing's sarcoma research: where are we now and what lies ahead? Cancer Res 2009;69(18):7140-50
63. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50(6):1198-206 .. Description of single agent testing of a Src inhibitor which is currently in clinical testing in combination with chemotherapeutic agents.
64. Aplenc R, Blaney SM, Strauss LC, et al. Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium. J Clin Oncol 2011;29(7):839-44
65. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50(4):799-805
66. Chawla SP, Staddon AP, Baker LH, et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol 2012;30(1):78-84
67. Spunt SL, Grupp SA, Vik TA, et al. Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. J Clin Oncol 2011;29(21):2933-40
68. Fouladi M, Laningham F, Wu J, et al. Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol 2007;25(30):4806-12
69. Mita MM, Mita AC, Chu QS, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 2008;26(3):361-7
70. Pignochino Y, Grignani G, Cavalloni G, et al. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer 2009;8:118
71. Grignani G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol 2012;23(2):508-16
72. Pignochino Y, Dell'aglio C, Basirico M, et al. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models. Clin Cancer Res 2013;19(8):2117-31
73. Xiao W, Mindrinos MN, Seok J, et al. A genomic storm in critically injured humans. J Exp Med 2011;208(13):2581-90
74. Currie GL, Delaney A, Bennett MI, et al. Animal models of bone cancer pain: systematic review and meta-analyses. Pain 2013;154(6):917-26